

Eva Ciruelos

1. Posicion actual

Coordinadora de la unidad de Unidad de cáncer de mama y ginecológico del Sº Oncología

- Jefa de grupo, laboratorio de oncología traslacional en tumores de mama, Instituto de Investigación Hospital 12 de Octubre (IMAS12).
- Coordinadora y Jefa de Unidad de mama en Hospitales HM, Madrid
- Profesor asociado Universidad Complutense de Madrid.
- Vicepresidente del grupo cooperativo SOLTI.
- Miembro de la Comité Científico de Grupo BIG de investigación en cáncer de mama.
- Miembro de Comité Científico reunión científica anual Sociedad Europea de Oncología Médica.
- Miembro de SEOM, ESMO y ASCO.
- Miembro y autor de panel de guías internacionales de manejo cáncer de mama (SEOM, San Gallen)

2. Formación Académica

1996

Licenciada en Medicina y Cirugía
Universidad Autónoma de Madrid

2001

Especialista en Oncología Médica
Hospital 12 de Octubre de Madrid

2004

Doctora en Medicina

UCM

2003

Experto Universitario en Gestión de Unidades Clínicas

UNED

2007

Master en Oncología Molecular

CNIO

2013

Master en Health Leadership Programme

IE Madrid

3. Publicaciones científicas (total, el Orcid y las 10 publicaciones mas relevantes)

WOS: H index : 42; 11.385 from 8.847 documents

Nº Pubmed indexed publicaciones: 137

D1: 50 (38%)

Q1: 77 (58%)

Q2: 32 (24%)

1st author 13

Senior author 12

Publicaciones más relevantes:

1. Scientific paper. (20/20). 2021. First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study. Front Oncol. 11. ISSN 2234-943X.

2 Scientific paper. (2/17). 2021. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. Ann Oncology. 32-10, pp.1245-1255. ISSN 1569-8041.

3 Scientific paper. (13/62). 2021. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 32-10, pp.1216-1235. ISSN 1569-8041.

- 4 Scientific paper. (1/19). 2021. Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1. *J Clin Oncol.* 39-18, pp.2005-2015. ISSN 1527-7755. <https://doi.org/10.1200/JCO.20.01139>
- 5 Scientific paper. (3/27). 2021. SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer. *Front Oncol.* 11. ISSN 2234-943X. <https://doi.org/10.3389/fonc.2021.638482>.
- 6 Scientific paper. André, F.; Ciruelos, E.M.; Juric, D.; et al; Rugo, H.S.(2/20). 2021. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1. *Annals of Oncology.* 32-2, pp.208-217. ISSN 1569-8041.
- 7 Scientific paper. (12/13). 2020. A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast Cancer. *Clin Cancer Res.* 26-23, pp.6141-6148. ISSN 1078-0432. <https://doi.org/10.1158/1078-0432>.
- 8 Scientific paper. Ciruelos E (AC); Galvan P; Martinez D; et al; Prat A. (1/18). 2020. Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial. *Clinical Cancer Research. American Association of Cancer Research.* 26-22, pp.5820-5829. ISSN 1078-0432. <https://doi.org/10.1158/1078-0432>
- 9 Scientific paper. Swain, S.M.; Miles, D.; Kim, S.-B.; et al; study group, CLEOPATRA; Ciruelos, E.(7/15). 2020. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. *The Lancet Oncology.* 21-4, pp.519-530. ISSN 1474-5488. [https://doi.org/10.1016/S1470-2045\(19\)30863-0](https://doi.org/10.1016/S1470-2045(19)30863-0)
- 10 Scientific paper. Ciruelos, E.M. (AC); Montaña, A.; Rodríguez, C.A.; et al; Casas, A.(1/19). 2020. Phase III study to evaluate patient's preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07). *European Journal of Cancer Care.* 29-4. ISSN 0961-5423. <https://doi.org/10.1111/ecc.13253>.
- 11 Scientific paper. André, F.; Ciruelos, E.; Rubovszky, G.; et al; Juric, D.(2/20). 2019. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. *New England Journal of Medicine.* 380-20, pp.1929-1940. ISSN 1533-4406.
- 12 Scientific paper. Prat, A.; Brase, J.C.; Cheng, Y.; et al; Ciruelos, E.; Ciruelos, E. (AC). (13/13). 2019. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2. *Oncologist.* 24-7, pp.893-900. ISSN 1083-7159. <https://doi.org/10.1634/theoncologist.2018-0407>
- 13 Scientific paper. Pascual, T.; Apellániz-Ruiz, M.; Pernaut, C.; et al; Ciruelos, E.; Ciruelos, E.

(AC). (11/11). 2017. Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer. PLoS ONE. 12-7. ISSN 19326203.
14 Scientific paper. Francis, P.A.; Regan, M.M.; Fleming, G.F.; et al; Gelber, R.D.; Ciruelos, E.(5/29). 2015. Adjuvant ovarian suppression in premenopausal breast cancer. New England Journal of Medicine. 372-5, pp.436-446. ISSN 1533-4406. <https://doi.org/10.1056/NEJMoa1412379>

4. Premios y becas como co/IP

1. Project. PI. PS 12/1016. Analysis of the prognostic value of a miRNA profile in node negative early breast cancer. (Instituto de Salud Carlos III). 2012-2015. 76.100 €.
- 2 Project. PI. Fundación MMA Analysis of polymorphisms and its correlation with efficacy and toxicity of everolimus in breast cancer.. (Mutua Madrileña). 2012-2014. 29.500 €.
- 3 Project. PI. Variation of molecular markers after neoadjuvant treatment in triple negative breast cancer.. (Mutua Madrileña). 2010-2012. 23.100 €.
- 4 Project. IIP. Analysis of miRNA pannel in patients with node-positive early breast cancer. PS09/1394. (Instituto de Salud Carlos III). 2009-2012. 74.400 €.
- 5 Project. DTS21/00111. A new platform to predict response to CDK4/6 inhibitors in metastatic breast cancer patients. From 09/02/2022.
- 6 Project. Ultrasensitive optoplasmonic immunoassay platform (Oncodeeplasm) for early detection of breast cancer based on protein biomarkers at the deep region of the blood proteome. Ministerio de Ciencia e Innovación. Investigación. (Hospital Universitario 12 de Octubre, CNIO, CSIC, Mecwins). From 13/01/2022. 485.000 €.
- 7 Project. AECC PROYECTOS COORDINADOS. TREATMENT OF ADVANCED BREAST CANCER WITH ADOPTIVE TRANSFER OF CD3+/PD1+ TUMOR-INFILTRATING LYMPHOCYTES (TILS 001 TRIAL. (Hospital 12 Octubre (coordinado)). From 09/01/2020. 997.700 €.
- 8 Project. PI. FIS 18/01408. Efficacy of CDK4/6 inhibitors in combination with hormonal treatment in luminal breast cancer : intrinsic subtype and immune biomarkers. (Instituto de Investigación 12 de Octubre). From 01/01/2019. 171.820 €.
- 9 Project. PI. FIS 15/1508. Gene expression analysis, miRNA and proteins in advanced breast cancer with known mutational profile. (Instituto de investigación 12 de Octubre). From 10/06/2015. 128.865 €.
- 10 Contract. Contrato Rio Hortega Instituto de Salud Carlos III.
11. Colaboración Fundación FERO – Mary Kay . Proyecto translacional de mecanismos de resistencia y sensibilidad a Trastuzumab Druvitecan. Octubre 2023. 50.000 €.